{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:34:10Z","timestamp":1793068450776,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Renal and hematological toxicity are side effects and dose-limiting factors of Peptide Receptor Radionuclide Therapy (PRRT). We aimed to assess the changes in renal and hematological function and associations with survival in neuroendocrine tumor (NET) patients treated with PRRT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort of 448 NET patients treated with either <jats:sup>177<\/jats:sup>Lu-DOTATATE or <jats:sup>90<\/jats:sup>Y-DOTATOC were followed for changes of renal and hematological function. Renal function was assessed by monitoring changes in serum creatinine, blood urea nitrogen and estimated glomerular filtration rate. Hematological function was determined by examining changes in white blood cell counts (WBC), platelet counts, and hemoglobin levels over time. Piecewise linear mixed effect models were applied to model the longitudinal repeated measurements of renal and hematological function. Overall survival (OS) and progression-free survival (PFS) were modelled using Cox proportional hazard regressions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 448 PRRT treated patients, 335 received <jats:sup>177<\/jats:sup>Lu-DOTATATE (74.78%) and 113 were treated with <jats:sup>90<\/jats:sup>Y-DOTATOC (25.22%). Comparing patients treated with <jats:sup>177<\/jats:sup>Lu-DOTATATE to those treated with <jats:sup>90<\/jats:sup>Y-DOTATOC, renal function did not differ significantly prior to, during or after PRRT. Compared with patients treated with <jats:sup>90<\/jats:sup>Y-DOTATOC, significantly decreased indicators of hematological function were observed in those treated with <jats:sup>177<\/jats:sup>Lu-DOTATATE prior to and during PRRT treatment (WBC: estimate, -0.10, 95% CI, -0.15 to -0.05; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001; platelet count: estimate, -2.53, 95% CI, -3.83 to -1.24; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and no significant recovery was observed in hematological function post PRRT. Individuals who received <jats:sup>177<\/jats:sup>Lu-DOTATATE tended to have a longer PFS (hazard ratio, 0.47, 95%CI: 0.28\u20130.79, <jats:italic>P<\/jats:italic>\u2009=\u20090.004) compared with <jats:sup>90<\/jats:sup>Y-DOTATOC, but there was no difference in OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>There was no significant renal, but minor hematological toxicity, in patients treated with <jats:sup>177<\/jats:sup>Lu-DOTATATE compared with <jats:sup>90<\/jats:sup>Y-DOTATOC. Compared to <jats:sup>90<\/jats:sup>Y-DOTATOC, <jats:sup>177<\/jats:sup>Lu-DOTATATE appears to enhance PFS, but not OS. Treatment with <jats:sup>177<\/jats:sup>Lu-DOTATATE may necessitate follow-up for hematological toxicity irrespective of other therapies prior to PRRT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-06020-w","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T21:18:39Z","timestamp":1730582319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Peptide Receptor Radionuclide Therapy and clinical associations with renal and hematological toxicities and survival in patients with neuroendocrine tumors: an analysis from two U.S. medical centers"],"prefix":"10.1007","volume":"150","author":[{"given":"Tao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Maluccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn E.","family":"Quelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H.","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunkeun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen E.","family":"Limbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Skill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Bren-Mattison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O\u2019Rorke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"issue":"10","key":"6020_CR2","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","volume":"43","author":"H Bergsma","year":"2016","unstructured":"Bergsma H, Konijnenberg MW, van der Zwan WA, Kam BL, Teunissen JJ, Kooij PP, Mauff KA, Krenning EP, Kwekkeboom DJ (2016) Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging 43(10):1802\u20131811","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"6020_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","volume":"43","author":"H Bergsma","year":"2016","unstructured":"Bergsma H, Konijnenberg MW, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Franssen GJ, van Eijck CH, Krenning EP, Kwekkeboom DJ (2016a) Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging 43(3):453\u2013463","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"6020_CR4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/BF03345728","volume":"32","author":"L Bodei","year":"2009","unstructured":"Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA, Paganelli G (2009) Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest 32(4):360\u2013369","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"6020_CR3","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","volume":"38","author":"L Bodei","year":"2011","unstructured":"Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, Bartolomei M, Lombardo D, Ferrari ME, Sansovini M, Chinol M, Paganelli G (2011) Peptide receptor radionuclide therapy with \u00b9\u2077\u2077Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging 38(12):2125\u20132135","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"6020_CR6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"L Bodei","year":"2013","unstructured":"Bodei L, Mueller-Brand J, Baum RP, Pavel ME, H\u00f6rsch D, O\u2019Dorisio MS, O\u2019Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40(5):800\u2013816","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6020_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","volume":"42","author":"L Bodei","year":"2015","unstructured":"Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, Lepensky C, Kwekkeboom DJ, Baum RP, Krenning EP, Modlin IM (2015) Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 42(1):5\u201319","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"16","key":"6020_CR7","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ (2017) Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res 23(16):4617\u20134624","journal-title":"Clin Cancer Res"},{"issue":"5","key":"6020_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","journal-title":"J Chronic Dis"},{"key":"6020_CR9","unstructured":"Commonwealth F (2019) U.S. Health Care from a Global Perspective, 2019. Commonwealth Fund"},{"issue":"13","key":"6020_CR10","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","volume":"45","author":"M Cremonesi","year":"2018","unstructured":"Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, Pacilio M, Strigari L, Summers PE, Orecchia R, Grana CM, Botta F (2018) Correlation of dose with toxicity and tumour response to (90)Y- and (177)Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging 45(13):2426\u20132441","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6020_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/annonc\/mdp372","volume":"21","author":"J \u0106wik\u0142a","year":"2010","unstructured":"\u0106wik\u0142a J, Sankowski A, Seklecka N, Buscombe J, Nasierowska-Guttmejer A, Jeziorski K, Miko\u0142ajczak R, Pawlak D, Walecki J (2010) Efficacy of radionuclide treatment 90Y-DOTATATE in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NET). A phase II study. Ann Oncol 21:787\u2013794","journal-title":"Ann Oncol"},{"issue":"4","key":"6020_CR12","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/MPA.0000000000000113","volume":"43","author":"ES Delpassand","year":"2014","unstructured":"Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, Erion JL, O\u2019Dorisio TM, Kvols LK, Simon J, Wolfangel R, Camp A, Krenning EP, Mojtahedi A (2014) Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas 43(4):518\u2013525","journal-title":"Pancreas"},{"issue":"6","key":"6020_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/oncolo\/oyab072","volume":"27","author":"H Duan","year":"2022","unstructured":"Duan H, Ferri V, Fisher GA, Shaheen S, Davidzon GA, Iagaru A, Mari Aparici C (2022) Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up. Oncologist 27(6):447\u2013452","journal-title":"Oncologist"},{"key":"6020_CR14","unstructured":"European Medicines Agency (2021) Authorization details for Lutathera in Europe. European Medicines Agency, from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lutathera#authorisation-details-section"},{"issue":"1","key":"6020_CR15","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","volume":"15","author":"A Frilling","year":"2014","unstructured":"Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R (2014) Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15(1):e8\u201321","journal-title":"Lancet Oncol"},{"issue":"4","key":"6020_CR16","first-page":"418","volume":"35","author":"LA Godley","year":"2008","unstructured":"Godley LA, Larson RA (2008) Therapy-related myeloid Leuk Semin Oncol 35(4):418\u2013429","journal-title":"Therapy-related myeloid Leuk Semin Oncol"},{"issue":"9","key":"6020_CR17","first-page":"593","volume":"27","author":"SK Gupta","year":"2012","unstructured":"Gupta SK, Singla S, Bal C (2012) Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE. Cancer Biother Radiopharm 27(9):593\u2013599","journal-title":"Cancer Biother Radiopharm"},{"issue":"7","key":"6020_CR18","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.118.230607","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, Lindsay S, Metz DC, Pryma DA, Stabin MG, Strosberg JR (2019) NANETS\/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE. J Nucl Med 60(7):937\u2013943","journal-title":"J Nucl Med"},{"issue":"17","key":"6020_CR19","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","volume":"29","author":"A Imhof","year":"2011","unstructured":"Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, M\u00e4cke HR, Rochlitz C, M\u00fcller-Brand J, Walter MA (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 29(17):2416\u20132423","journal-title":"J Clin Oncol"},{"issue":"11","key":"6020_CR20","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1002\/cncr.34191","volume":"128","author":"KR Kennedy","year":"2022","unstructured":"Kennedy KR, Turner JH, MacDonald WBG, Claringbold PG, Boardman G, Ransom DT (2022) Long-term survival and toxicity in patients with neuroendocrine tumors treated with (177) Lu-octreotate peptide radionuclide therapy. Cancer 128(11):2182\u20132192","journal-title":"Cancer"},{"issue":"2","key":"6020_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000362558","volume":"99","author":"M Kesavan","year":"2014","unstructured":"Kesavan M, Claringbold PG, Turner JH (2014) Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up. Neuroendocrinology 99(2):108\u2013117","journal-title":"Neuroendocrinology"},{"key":"6020_CR22","volume-title":"SOC NUCLEAR MEDICINE INC 1850 SAMUEL MORSE DR","author":"D Kwekkeboom","year":"2003","unstructured":"Kwekkeboom D, Bakker W, Teunissen J, Kooij P, Krenning E (2003) Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with neuroendocrine tumors: Interim results. SOC NUCLEAR MEDICINE INC 1850 SAMUEL MORSE DR. JOURNAL OF NUCLEAR MEDICINE, RESTON, VA 20190\u2009\u2013\u20095316 USA"},{"issue":"Suppl 1","key":"6020_CR24","first-page":"62s","volume":"46","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O\u2019Dorisio M, Valkema TR, Bodei L, Chinol M, Maecke HR, Krenning EP (2005a) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46(Suppl 1):62s\u201366s","journal-title":"J Nucl Med"},{"issue":"12","key":"6020_CR25","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","volume":"23","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser J-P, Kam BL, Krenning EP (2005b) Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23(12):2754\u20132762","journal-title":"J Clin Oncol"},{"issue":"13","key":"6020_CR23","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26(13):2124\u20132130","journal-title":"J Clin Oncol"},{"key":"6020_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1479-5876-11-17","volume":"11","author":"N Marincek","year":"2013","unstructured":"Marincek N, J\u00f6rg AC, Brunner P, Schindler C, Koller MT, Rochlitz C, M\u00fcller-Brand J, Maecke HR, Briel M, Walter MA (2013) Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med 11:17","journal-title":"J Transl Med"},{"issue":"4","key":"6020_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0272-6386(01)80135-9","volume":"37","author":"S Moll","year":"2001","unstructured":"Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ (2001) A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 37(4):847\u2013851","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"6020_CR28","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s002590050476","volume":"26","author":"A Otte","year":"1999","unstructured":"Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Muller J (1999) Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 26(11):1439\u20131447","journal-title":"Eur J Nucl Med"},{"issue":"3","key":"6020_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000324096","volume":"93","author":"AK Pfeifer","year":"2011","unstructured":"Pfeifer AK, Gregersen T, Gr\u00f8nb\u00e6k H, Hansen CP, M\u00fcller-Brand J, Herskind Bruun K, Krogh K, Kj\u00e6r A, Knigge U (2011) Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology 93(3):189\u2013196","journal-title":"Neuroendocrinology"},{"key":"6020_CR30","doi-asserted-by":"publisher","first-page":"861434","DOI":"10.3389\/fendo.2022.861434","volume":"13","author":"G Puliani","year":"2022","unstructured":"Puliani G, Chiefari A, Mormando M, Bianchini M, Lauretta R, Appetecchia M (2022) New Insights in PRRT: Lessons From 2021. Front Endocrinol (Lausanne) 13:861434","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"6020_CR31","doi-asserted-by":"publisher","first-page":"e220290","DOI":"10.1001\/jamanetworkopen.2022.0290","volume":"5","author":"S Pusceddu","year":"2022","unstructured":"Pusceddu S, Prinzi N, Tafuto S, Ibrahim T, Filice A, Brizzi MP, Panzuto F, Baldari S, Grana CM, Campana D, Dav\u00ec MV, Giuffrida D, Zatelli MC, Partelli S, Razzore P, Marconcini R, Massironi S, Gelsomino F, Faggiano A, Giannetta E, Bajetta E, Grimaldi F, Cives M, Cirillo F, Perfetti V, Corti F, Ricci C, Giacomelli L, Porcu L, Di Maio M, Seregni E, Maccauro M, Lastoria S, Bongiovanni A, Versari A, Persano I, Rinzivillo M, Pignata SA, Rocca PA, Lamberti G, Cingarlini S, Puliafito I, Ambrosio MR, Zanata I, Bracigliano A, Severi S, Spada F, Andreasi V, Modica R, Scalorbi F, Milione M, Sabella G, Coppa J, Casadei R, Di Bartolomeo M, Falconi M, de Braud F (2022) Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. JAMA Netw Open 5(2):e220290","journal-title":"JAMA Netw Open"},{"issue":"2","key":"6020_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00259-013-2559-8","volume":"41","author":"A Romer","year":"2014","unstructured":"Romer A, Seiler D, Marincek N, Brunner P, Koller MT, Ng QK, Maecke HR, M\u00fcller-Brand J, Rochlitz C, Briel M, Schindler C, Walter MA (2014) Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 41(2):214\u2013222","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"6020_CR33","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","volume":"54","author":"A Sabet","year":"2013","unstructured":"Sabet A, Ezziddin K, Pape UF, Ahmadzadehfar H, Mayer K, P\u00f6ppel T, Guhlke S, Biersack HJ, Ezziddin S (2013) Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med 54(11):1857\u20131861","journal-title":"J Nucl Med"},{"issue":"3","key":"6020_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00259-013-2601-x","volume":"41","author":"A Sabet","year":"2014","unstructured":"Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H, Biersack HJ, Nagarajah J, Ezziddin S (2014) Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. Eur J Nucl Med Mol Imaging 41(3):505\u2013510","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6020_CR35","unstructured":"SEER (2015) Surveillance, epidemiology, and end results program. Pancreas Cancer Stat Fact Sheets"},{"issue":"12","key":"6020_CR36","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP (2021) (177)Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22(12):1752\u20131763","journal-title":"Lancet Oncol"},{"key":"6020_CR37","unstructured":"US Food and Drug Administration (2018) FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS. from https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lutetium-lu-177-dotatate-treatment-gep-nets"},{"issue":"2","key":"6020_CR38","first-page":"295","volume":"18","author":"R Valkema","year":"2003","unstructured":"Valkema R, Jamar F, Pauwels S, Kvols L, Barone R, Bakker W, Lasher J, Krenning E (2003) Phase 1 study of peptide receptor radionuclide therapy (PRRT) with [Y-90-DOTA, tyr (3)] octreotide in patients with somatostatin receptor positive tumors. Cancer Biother Radiopharm 18(2):295","journal-title":"Cancer Biother Radiopharm"},{"issue":"Suppl 1","key":"6020_CR39","first-page":"83s","volume":"46","author":"R Valkema","year":"2005","unstructured":"Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PP, Bakker WH, Lasher J, Krenning EP (2005) Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 46(Suppl 1):83s\u201391s","journal-title":"J Nucl Med"},{"key":"6020_CR40","doi-asserted-by":"crossref","unstructured":"Wu C, Song Z, Balachandra S, Dream S, Chen H, Rose JB, Bhatia S, Gillis A (2024) Charting the Course: Insights into Neuroendocrine Tumor Dynamics in the United States. Ann Surg.","DOI":"10.1097\/SLA.0000000000006331"},{"issue":"18","key":"6020_CR41","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063\u20133072","journal-title":"J Clin Oncol"},{"issue":"5","key":"6020_CR42","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.1097\/RLU.0000000000002532","volume":"44","author":"A Yordanova","year":"2019","unstructured":"Yordanova A, Ahrens H, Feldmann G, Brossart P, Gaertner FC, Fottner C, Weber MM, Ahmadzadehfar H, Schreckenberger M, Miederer M, Essler M (2019) Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors. Clin Nucl Med 44(5):e329\u2013e335","journal-title":"Clin Nucl Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-06020-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-06020-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-06020-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T08:10:20Z","timestamp":1732090220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-06020-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["6020"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-06020-w","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki. This study was approved by the University of Iowa Institutional Review Board (IRB ID: 199911057) and operated under a data use agreement with LSU.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"485"}}